Clinical update of biotherapy for renal cell carcinoma / 肿瘤研究与临床

ABSTRACT

Biotherapy is an effective treatment strategy for advanced renal cell carcinoma. Cytokine-based biotherapy with interleukin-2 and interferon-? is the first line treatment for renal cell carcinoma, but its response rate is still low and toxicity and side effects are relatively high. Among preclinical biotherapy approaches for renal cell carcinoma, targeted therapy is a promising measure and some new drugs will be used as first line treatment for renal cell carcinoma in near future, allogeneic stem cell transplantation and vaccination are effective for selected subset of patients but are necessary to be evaluated by phase Ⅲ clinical studies, adoptive immunotherapy and gene therapy need to establish the benefit and safe by further studies.